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Abstract
Background: Excessive activity of dendritic cells (DCs) is postulated as a central disease mechanism in Systemic Lupus
Erythematosus (SLE). Vitamin D is known to reduce responsiveness of healthy donor DCs to the stimulatory effects of Type I
IFN. As vitamin D deficiency is reportedly common in SLE, we hypothesized that vitamin D might play a regulatory role in
the IFNa amplification loop in SLE. Our goals were to investigate the relationship between vitamin D levels and disease
activity in SLE patients and to investigate the effects of vitamin D on DC activation and expression of IFNa-regulated genes
in vitro.
Methodology/Principal Findings: In this study, 25-OH vitamin D (25-D) levels were measured in 198 consecutively recruited
SLE patients. Respectively, 29.3% and 11.8% of African American and Hispanic SLE patient had 25-D levels ,10 ng/ml. The
degree of vitamin D deficiency correlated inversely with disease activity; R=2.234, p=.002. In 19 SLE patients stratified by
25-D levels, there were no differences between circulating DC number and phenotype. Monocyte-derived DCs (MDDCs) of
SLE patients were normally responsive to the regulatory effects of vitamin D in vitro as evidenced by decreased activation in
response to LPS stimulation in the presence of 1,25-D. Additionally, vitamin D conditioning reduced expression of IFNa-
regulated genes by healthy donor and SLE MDDCs in response to factors in activating SLE plasma.
Conclusions/Significance: We report on severe 25-D deficiency in a substantial percentage of SLE patients tested and
demonstrate an inverse correlation with disease activity. Our results suggest that vitamin D supplementation will contribute
to restoring immune homeostasis in SLE patients through its inhibitory effects on DC maturation and activation. We are
encouraged to support the importance of adequate vitamin D supplementation and the need for a clinical trial to assess
whether vitamin D supplementation affects IFNa activity in vivo and, most importantly, improves clinical outcome.
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Introduction
Although patients with Systemic Lupus Erythematosus (SLE)
exhibit diverse clinical and serologic manifestations, they share
immunologic abnormalities resulting in loss of tolerance, auto-
reactivity, inflammatory sequelae and organ dysfunction. Non-toxic
immunomodulatory modalities would be a welcome addition to the
current agents used to manage autoimmune disease. Interferon
alpha (IFNa) has multiple pro-inflammatory and permissive effects
on autoreactive cells and has emerged as a central player in the
progression to and maintenance of autoimmunity. It is produced in
large amounts by activated plasmacytoid dendritic cells (pDCs).
Therefore, therapies targeting IFNa and pDCs are currently in
development for treatment of SLE. We and others are interested in
the potential role of vitamin D deficiency in the development and
perpetuation of SLE. In addition to its regulatory role in calcium
balance and bone metabolism, vitamin D has immunomodulatory
effects that help maintain immune homeostasis. We are particularly
interested in the potential susceptibility of lupus pDCs to
immunomodulation with vitamin D.
Vitamin D is a steroid hormone recognized as essential for bone
and mineral homeostasis. Although small amounts of vitamin D are
provided in the normal diet, the major portion is produced through
the action of ultraviolet B radiation effects in the skin leading to the
generation of cholecalciferol, the inert vitamin D precursor (vitamin
D3). In the liver, a non-essential mitochondrial enzyme (CYP27A1)
and an essential microsomal enzyme (CYP 2R1) convert Vitamin
D3 to 25-hydroxy vitamin D (25-D). In renal tubule cells, 25-D is
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metabolite, calcitriol, by 1-alpha vitamin D hydroxylase
(CYP27B1), Circulating levels of 1,25-D are controlled through
complex mechanisms involving parathyroid hormone, calcium and
phosphate concentrations, and self regulation which protect against
vitamin D toxicity. Most of the biological effects of 1, 25-D are
mediated through its interaction with the vitamin D receptor
(VDR). In addition to cells in the gut and bone, the VDR is present
in numerous cell types, including those of the immune system. It
functions as an agonist-activated transcription factor that binds to
vitamin D response elements in the promoters of many genes [1].
The immune system has all of the components needed to utilize
vitamin D as an autocrine and paracrine signaling system. The
VDR is expressed in T and B lymphocytes[2] and on monocytes
differentiating into dendritic cells (DCs)[3]. Mature DCs express
both CYP27A1 and CYP27B1and therefore are capable of locally
generatingtheactive1, 25-D hormone from vitamin D3 [4].In fact,
in vitro, cultures of healthy donor DCs convert vitamin D3 into levels
of 1, 25-D that are substantially higher than those typically
measured in human serum providing further support that local
generation of 1, 25-D at sites of an immune response may be a
potential mechanism for modulating the immune system. Hormon-
ally active vitamin D inhibits several components of the immune
system[4,5] including DC differentiation and maturation [6], B cell
differentiation [7], T cell proliferation in response to T cell receptor
(TCR) stimulation[2]andsecretionofIL-12andTNFa whileIL-10
production is maintained[8]. Consistent with these findings, the
hormone promotesTh-2 typeT cell responses[9]andmaypromote
generation of regulatory T cells [10].
A number of studies suggest that administration of vitamin D
ameliorates inflammation in animal models of autoimmune diseases
including lupus[11,12,13], multiple sclerosis[14,15], and inflamma-
tory bowel disease[16]. Vitamin D additionally inhibits graft re-
jection in multiple models of organ transplant (17). These animals
studies are complemented by human epidemiologic studies demon-
strating an inverse correlation between vitaminD intake with risk for
multiple sclerosis[17], type 1 diabetes[18], and rheumatoid arthri-
tis[19]. Although interventional studies using vitamin D as therapy
for autoimmune disease are limited, short open label trials pro-
vide promising results in multiple sclerosis[20], psoriasis[21], and
rheumatoid arthritis[22].
1,25-Dhassuppressiveeffectsonmonocytesfromhealthydonors
and inhibits IFNa-mediated monocyte differentiation into DCs.
The effects of vitamin D on monocytes from autoimmune patients
such as SLE are unknown. DCs comprise an integral link between
innate and adaptive immune responses and can perpetuate an auto-
inflammatory response. Immune complexes containing nucleic
acids from apoptotic or necrotic cells trigger the production of
IFNa. FollowingFccR-mediated endocytosisand activation of Toll-
like receptors (TLR) 7 and 9, pDCs are stimulated to release IFNa,
that in turn promotes further differentiation of monocytes into
DCs[23,24]. Activated DCs can subsequently prime and polarize
naı ¨ve T cells through expression of co-stimulatory molecules, and
secretion of cytokines including IL-12, IL-10 or IL-23. Activated
DCs will additionally promote activation and expansion of
autoreactive T and B cells which sustain autoantibody production
and continued release of IFNa[25,26]. The central role of IFNa in
SLE is clinically supported by observations that treatment with
IFNa frequently results in autoimmune effects and, in some, a
lupus-like disease. It is also clear that IFN inducible genes are over-
expressed in peripheral blood mononuclear cells (PBMCs) in SLE
patients [27,28,29,30,31]. This ‘‘IFN signature’’ correlates with
disease activity and severity[32], suggesting that over production of
this cytokine may be a driving force in SLE pathogenesis.
Vitamin D deficiency has been reported in patients with
SLE[33] and it is known that 1, 25-D reduces healthy donor DC
responses to Type I IFN maturation signals in vitro[6]. We
hypothesized that vitamin D plays a regulatory role in the IFNa
amplification loop in SLE patients. Our goals were to investigate
the relationship between vitamin D levels and disease activity in
SLE patients and to investigate whether vitamin D can modulate
maturation and induction of the IFN signature in monocyte-
derived DC (MDDC) from SLE patients. We describe a series of
experiments that suggest the possibility that vitamin D supple-




Consecutively encountered patients meeting ACR classification
criteria for SLE were identified at three medical centers: the
Medical University of South Carolina (Charleston, SC), the NIH
clinical center (Bethesda, MD) and at the Montefiore Medical
Center (Bronx, NY). Patients with a serum creatinine greater than
2.0 mg/dl were excluded. 198 subjects were recruited for analysis
of 25-D levels and disease activity. Serum 25-D levels were assayed
by the individual clinical center laboratories. Disease activity,
measured using the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI), patient demographics and medication
use were also collected (Table 1). Prednisone dose was available for
144 subjects. Blood samples for the studies described below were
collected from additional SLE patients and healthy controls at
Columbia University Medical Center (New York, NY) and Jacobi
Medical Center (Bronx, NY). All Phenotypic analysis of DCs:
Heparanized blood (30 ml) was collected from 19 SLE patients
with both stable disease activity and therapeutic regimens.
Mononuclear cells were isolated over Ficoll-Hypaque and
recovered cells were stained with flurochrome conjugated
antibodies to CD11c, CD40, CD86, and HLA-DR and were
analyzed by flow cytometry after gating on CD11c
+ cells.
Generation of Monocyte Derived DC (MDDC)
Monocytes from SLE subjects and healthy donors were isolated
from PBMC using RosetteSep Human Monocyte Enrichment
Cocktail (StemCellTechnologies, Vancouver, Canada) according
to the manufacturer’s protocol. They were then cultured with
0.1 mg/ml IL-4 (Peprotech, Rocky Hill, NJ) and 0.27 mg/ml GM-
CSF (Peprotech) for 5–7 days. Flow cytometry demonstrated a cell
population comprised of 90% CD11c
+ cells.
MDDC Activation Response: To study the effect of vitamin D
on MDDC activation, MDDCs from 3 SLE patients were cultured
with and without a 10 nM concentration of 1,25-D and stimulated
with lipopolysacharide (LPS, Sigma) at a concentration of 50 ng/
ml for 2 days. Surface activation markers, CD40, CD86 and HLA-
DR were measured using flow cytometry.
IFN Inducible Genes
1, 25-D-exposed or non-exposed MDDC from two healthy
controls and two SLE subjects were incubated at 37uC for 4 hours
with ‘‘activating plasma’’, SLE plasma known to transfer the IFN
signature, or healthy control plasma (20%) for 4 hours.. The
incubation was performed in a 96 well flat bottom plate (Falcon,
Franklin Lakes, NJ) with 5610
5 cells/100 ml /well in Eagles
Minimum Essential Medium (EMEM) modified to contain Earl’s
balanced salt solution, non-essential amino acids, 2 mM L-
glutamine, 1 mM sodium pyruvate and 1500 mg/l sodium
bicarbonate supplemented with 10% FBS and 1% Penicillin G
Vit D, Dendritic Cells, SLE
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incubation with activating SLE plasma or healthy control plasma,
RNA was extracted from the 1, 25-D exposed and non-exposed
MDDC using Picopure RNA isolation kits (Arcturus Bioscience,
Mountain. View, CA) followed by reverse transcription to generate
complementary DNA (cDNA) in a 20 ml reaction using the iScript
cDNA synthesis kit (BioRad, Hercules, CA). The cDNA was
further subjected to quantitative PCR on a Bio-Rad Myiq cycler.
Triplicates samples of cDNA were diluted 1:10, and 7 ml was
amplified in a 21 ml reaction mix using 2X TaqMan Universal
PCR Master mix (Applied Biosystems, Foster City, CA) and 20X
TaqMan Gene expression assay mix. Three IFNa-regulated genes
were identified as target genes: Ifit1 (interferon induced protein
with tetricopeptide repeats 1; Hs01675197 m1), Mx1 (myxovirus
resistance 1; Hs00182073 m1) and Ifi44 (interferon induced
protein 44; Hs00197427m1). These genes have been identified
as highly and specifically induced by IFNa[34]. Expression of
HPRT1 (hypoxanthine phosphoribosyltransferase 1) was moni-
tored as the housekeeping gene. Relative expression of target genes
was calculated using the comparative threshold cycle method.
Ethics
The individual participants in this study gave written consent
prior to any study procedures. Approval for the study was obtained
from the National Institute of Health Sciences Institutional Review
Board, the Committee on Clinical Investigations at the Albert
Einstein College of Medicine and the Institutional Review Board
for Human Research at the Medical University of South Carolina.
As many of the translational studies were conducted at the
Feinstein Institute for Medical Research, additional approval was
obtained from the North Shore-Long Island Jewish IRB.
Statistical Analysis
Correlations were determined by Pearson product moment
correlation for interval data and by Spearman rank order
correlation for ordinal data or for interval data, which did not
follow a normal distribution. Nominal data were analyzed by chi-
square analysis-of-contingency tables. Non-parametric Mann-
Whitney tests were used for the between group comparison of
surface markers in the DC phenotype.
Results
Vitamin D Deficiency Is Prevalent among Patients with
SLE and Correlates with Increased Disease Activity
We obtained clinical and laboratory data on 198 consecutively
encountered patients meeting ACR classification criteria for SLE.
The majority were African Americans (71%) or Hispanics (21%)
with relatively small numbers of Caucasians and Asians. The four
racial groups had similar gender, age, renal function, SLE disease
activity score (SLEDAI), serological findings and corticosteroid
dose (Table 1).
Non-normalized median 25-D levels were lowest among African
Americans (14.2 ng/ml, IQR 9.1–19) and Hispanics (20.5 ng/ml,
IQR 13–30) and highest among Asians (22 ng/ml, IQR 11.5–29.5)
and Caucasians (29 ng/ml, IQR 14.5–34) (Figure 1A). The prevalence
of severe vitamin D deficiency among African Americans and
Hispanics with SLE was striking; 29.3% and 11.8% respectively had
25-D levels less than 10 ng/ml. This level of deficiency was not
observed among Asians and Caucasians (Figure 1B). Vitamin D levels
correlated inversely with disease activity measured by SLEDAI
(r=2.243,p=.002) even after controlling for ethnicity and prednisone
dose (Figure 1C). There were no significant differences in 25-D blood
levels between African Americans in South Carolina and those in the
Bronx (data not shown).
Circulating pDC and mDC Numbers and Phenotypes in
SLE Are Not Affected by Vitamin D Levels
Previous studies of patients with SLE have demonstrated a fairly
consistent decrease in circulating plasmacytoid DCs (pDCs) and a
variable decrease in myeloid DCs (mDCs) compared to normal
controls [35]. In addition, MDDCs from SLE patients are
reported to be functionally different from normal DCs[36,37].
Therefore, we initially sought to determine if vitamin D deficiency
is associated with any major shifts in DC phenotypes. Peripheral
blood mDCs and pDCs from 19 SLE patients were isolated by
Table 1. Demographic and clinical characteristics of the patients.
MMC and NIH groups MUSC group
Race Asians African Americans Caucasians Hispanics African Americans
Number of Patients (%) 6(6) 40(41) 10(10) 42(43) 100(100)
Age. Years (range) 41.8(19–53) 40.4(21–61) 48.7(17–69) 43.4(19–69) 39.1(10–70)
Female, no. 5 38 8 39 94
Male, no. 1 2 2 3 6
C3 mg/dl (range) 109(100–119) 100.5(27–162) 93.1(62–137) 97.14(38–166) –
C4 mg/dl (range) 29(20–41) 23.6(7.8–48) 10(11–41) 22.44(7.8–68) –
CH50 mg/dl (range) – – – – 25.7(0–59)
dsDNA, % positive 17 47 38 40 30
Serum creatinine mg/dl (range) 0.8(0.7–1.2) 0.9(0.5–1.8) 0.95(0.7–1.4) 0.9(0.5–1.8) –
SLEDAI, median (range) 0(0–2) 2(0–22) 2(0–6) 4(0–10) 2(0–28)
Patients taking prednisone, no. (%) 6(100) 20(80) 7(70) 37(88) –
Mean daily dose of prednisone in mg 5.2 18.2 8.5 15 –
Except where indicated otherwise, values are the mean (range). MMC = Montefiore Medical Center, NIH = National Institutes of Health.
MUSC = Medical University of South Carolina; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index.
dsDNA = anti-double-stranded DNA.
doi:10.1371/journal.pone.0009193.t001
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pDCs and mDCs were compared between groups stratified by
25-D levels of ,20 ng/ml (n=13) and .30 ng/ml (n=6). All
patients were on stable treatment regimens for SLE and both
groups had comparable levels of disease activity. There were no
significant differences in the numbers of circulating mDCs or
pDCs between these two groups or any differences in expression of
activation markers HLA-DR, CD-40, or CD-86 (data not shown).
SLE MDDC Activation by LPS Is Modulated by 1,25-D
It has been previously reported that 1, 25-OH D3 added to
healthy donor monocytes cultured in vitro with type I IFN and
GM-CSF has a suppressive effect on MDDC maturation,
differentiation and activation resulting in impaired LPS-induced
production of Th-1 polarizing cytokines (5, 6). To determine
whether the monocyte-DC axis in SLE patients is normally
responsive to vitamin D, MDDC from 3 African American SLE
subjects were prepared in the presence or absence of 10 nm 1,
25-D, followed by LPS stimulation. These patients had minimal
disease activity (with SLEDAI #4), all were on low dose
prednisone (#10 mg/day) and two were on immunosuppressive
medications (cellcept and azathioprine). Two of them had serum
25-D levels less than 30 ng/ml. Expression of activation markers
HLA-DRII, CD40, and CD86 were measured by flow cytometry.
Results are shown in Figure 2A; representative flow cytometry
data for one subject is shown in Figure 2B. In the 3 lupus patients
studied, MDDCs responded to LPS stimulation with increased
expression of HLA-DRII, CD40, and CD86. This maturation
response was blocked effectively by 1, 25-D as reported previously
for DCs from non-autoimmune individuals[5]. Thus, MDDCs
derived from SLE patients behave similarly to healthy donor
MDDCs and are responsive to the constraints on maturation
imposed by vitamin D.
Vitamin D Inhibits Transfer of the IFN Signature to
Healthy Donor and SLE MDDC In Vitro
Type I interferons induce monocyte differentiation into DCs[6].
The ability of some lupus sera/plasma to induce DC differenti-
ation has been attributed, at least in part, to the presence of IFNa
and/or immune complexes within SLE sera that may trigger
intracellular toll-like receptors(TLRs) and stimulate increased
IFNa expression [38]. We assessed the impact of Vitamin D on
the expression of IFN regulated genes (Mx1, Ifit1, Ifi44) induced
by SLE activating plasma in healthy donor or SLE MDDCs.
MDDCs from two healthy donors and two SLE subjects, exposed
or non-exposed to 1, 25 D were incubated with activating SLE
plasma or control plasma for 4 hours. One of these SLE patients
had active renal disease (SLEDAI score 10), the other was
clinically quiescent with a SLEDAI score of 0 and both had low
serum levels of 25-D (24 and 19 ng/ml). As expected, healthy
donor MDDC exhibited an increased expression of IFNa
inducible genes when incubated with SLE activating plasma
compared to healthy donor plasma (Figure 3A). This responsive-
ness to the stimulatory effects of SLE plasma was largely reversed
in DC exposed to 1, 25-D (Figure 3A). Gene expression of
MDDCs from both SLE subjects, one with active and one with
inactive disease, was similarly responsive to stimulation with SLE
activating plasma and modulation with 1, 25-D (Figure 3B).
Overall percent reduction in gene expression modulated by the
addition of 1, 25-D in healthy donor and SLE MDDCs was 62%,
Figure 1. Assessment of 25-D levels in patients with SLE. The distribution and median blood level for 25-D (+/2 1 SD) is shown for each ethnic
group (A). Severe vitamin D deficiency (defined as a blood level of 25-D less than 10 ng/ml) is most prevalent among African American and Hispanic
patients (B). Disease activity scores (SLEDAI) exhibited an inverse correlation with 25-D levels (C).
doi:10.1371/journal.pone.0009193.g001
Vit D, Dendritic Cells, SLE
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evidence that MDDCs of SLE patients are responsive to the
inhibitory effects of vitamin D.
Discussion
It is well established that vitamin D is important for bone
mineralization and homeostasis. Additional evidence is accumu-
lating to suggest that this vitamin is important for many other
aspects of health, including immune regulation. However, there
are scarce data on the effects of vitamin D supplementation on the
clinical status of patients with an autoimmune disorder. The
present study provides support that vitamin D supplementation
may help normalize immunologic abnormalities of SLE patients
and offers insight into an immunomodulatory mechanism for
vitamin D.
Our observations regarding vitamin D deficiency in SLE are
consistent with previous reports of a high prevalence of vita-
min D deficiency in SLE, particularly in African Americans
[33,39,40,41,42,43]. We found that 29% of African Americans
with SLE from three centers had blood levels of 25-D less than
10 ng/ml compared to a previously reported prevalence of 12.1%
in the same ethnic group in the NHANES III survey of healthy
women of child bearing age [44]. Melanin is known to inversely
correlate with endogenous production of vitamin D and lower
serum levels of 25-D[45]. The striking prevalence of severely low
vitamin D in African Americans with SLE may reflect additional
non-identified disease related factors that further compromise
body stores of vitamin D[45]. There was no discernable effect of
sun exposure experienced by patients living at different latitudes
on blood levels of 25-D in our patient cohorts although the study
was not designed to assess this issue and lupus patients are
routinely advised to avoid UV radiation.
Other studies have investigated the prevalence of vitamin D
deficiency in SLE, and looked at a potential corrrelation of vitamin
D levels with disease activity. Most, but not all, have reported an
inverse correlation between disease activity and vitamin D levels
[40,46,47,48]. Our data confirm an inverse correlation between
25-D and disease activity. We have demonstrated that vitamin D
deficiency may be permissive for increased disease activity in SLE
because of its effects on the IFNa axis regulating DC differenti-
ation and maturation. However, it is possible that the low vitamin
D levels observed are reflective of an ongoing inflammatory
process. Inflammation per se potentially enhances vitamin D
catabolism[49] and anti-vitamin D antibodies have been reported
in SLE patients[50]. SLE patients with more active disease are
likely to receive higher corticosteroid doses. Our study did not
show an association of corticosteroid use with serum vitamin 1,
25-D levels. It is possible that patients with greater disease activity
spend less time in sun-exposed environments. Our data do not
Figure 2. MDDCs from patients with lupus are responsive to the suppressive effects of vitamin D. DCs were prepared from monocytes of
3 African American patients with SLE (C8, C25, and C26) in the presence or absence of a 10 nM concentration of 1, 25-D and exposed to LPS as a
maturation stimulus. Cells were analyzed for expression of HLA-DR II, CD40, and CD86 using flow cytometry. Composite results are shown as the
relative value for mean fluorescent index compared to cells not exposed to vitamin D or LPS (A). The histogram data for one representative patient is
shown (B). C8 was taking cellcept 3 gm/day and prednisone 5 mg/day, C25 was taking azathioprine 150 mg/day and prednisone 5 mg/day and C26
was taking methylprednisolone 8 mg/day. SLEDAI scores for C8 and C25 were 0 and the SLEDAI score for C26 was 4.
doi:10.1371/journal.pone.0009193.g002
Vit D, Dendritic Cells, SLE
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levels in patients in different latitudes.
Given the strong evidence for a fundamental role of IFNa in
disease pathogenesis, we investigated the effects of vitamin D on
DCs, specifically upon MDDC maturation and activation and on
IFNa activity in vitro. Prior to investigating the potential effects of
IFNa on MDDCs, we established that circulating DC numbers
and phenotype in vivo were not affected by serum levels of vitamin
D. Two groups of SLE subjects stratified by 25-D levels with
comparable medication doses and disease activity had equivocal
numbers and surface expression markers of mDCs and pDCs. The
focus of the remainder of our studies was on the effects of vitamin
D on MDDCs. We report that lupus MDDCS behave similarly to
normal MDDCs and are responsive to the effects of vitamin D in
vitro. Vitamin D exposure promotes an immature, tolerogenic DC
phenotype. Vitamin D additionally inhibits the overexpression of
INF inducible genes. These investigations are clearly limited by
the small numbers of samples studied. However, the consistency of
the data, from both lupus and normal controls strongly suggests
that our analyses are not incidental findings.
IFNa is a pleiotropic Type I interferon that has been implicated
in SLE disease pathogenesis. As previously discussed, treatment of
malignancy and chronic hepatitis with recombinant IFNa resulted
in increased autoantibody production and, occasionally, clinical
features suggestive of SLE that resolve following cessation of
treatment[51]. It is also known that IFNa has the ability to
regulate DC differentiation after phagocytosis of apoptotic self-
debris leading to a break in tolerance[38]. Nucleic acid containing
immune complexes are also able to stimulate DCs through TLR
activation and result in increased IFNa production. IFNa then
drives differentiation and maturation of mDCs in an autocrine
fashion, resulting in stimulation of autoreactive T and B cells and
further immune complex formation[52]. Many SLE patients have
evidence of increased IFNa activity demonstrated by the
overexpression of IFNa regulated genes (the IFN signature)[28]
or increased serum IFNa levels. Familial aggregation of high IFNa
serum levels as well as the presence of the IFNa signature among
SLE patients and families suggests heritable risk factors related to
IFNa[53]. Several recently identified SLE susceptibility genes
including IRF5, STAT4 and PTPN22 are associated with
increased serum IFNa activity that is related to IFNa production
and downstream sensitivity to IFNa[54,55,56].
Vitamin D potentially regulates MDDCs by several mechanisms
including effects on the nuclear factor-kB (NF-kB) transcription
factor, RelB. The RelB promoter region contains a VDR binding
site; ligation of the VDR at this sites reduced transcription of
RelB[57]. RelB is an essential element for DC differentiation and
maturation and is known to regulate MDDC subset development
Figure 3. Vitamin D inhibits the induction of an IFN signature in MDDCs exposed to activating SLE plasma. Relative expression of three
IFN inducible genes, compared to the housekeeping gene HPRT1, is shown in MDDC from 2 healthy donors cultured in the presence or absence of 1,
25-D at a concentration of 10 nM followed by exposure to activating SLE plasma or healthy donor plasma (Figure 3A). MDDC from 2 SLE subjects
were subjected to an identical sequence of events (Figure 3B). One of these patients was an African American female with active renal disease, a
SLEDAI of 10 and a serum 25-D level of 24. The other was a Hispanic female with SLEDAI score of 0 and a serum 25-D level of 19. Although expression
of the 3 IFNa targeted genes appears to differ between healthy MDDC and SLE MDDC, overall expression is reduced with the addition of physiologic
levels of Vitamin D during MDDC culture.
doi:10.1371/journal.pone.0009193.g003
Vit D, Dendritic Cells, SLE
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IkBa, potentially reducing cellular sensitivity to ligands that
depend upon NF-kB signaling pathways[61]. In addition, vitamin
D modulates expression of TLRs whose signals synergize with
IFNa responses[62] and down regulate the type 1 interleukin-1
receptor [63] which serves a stimulatory role in the TLR
cascade[64]. Finally, vitamin D reduces expression of many genes
that are important for the amplification of the immune response
including IL-2, IFNa, and CD40.
It is certainly appealing to consider that the mechanism by
which vitamin D repletion might benefit patients with autoimmu-
nity is based on the ability of DCs and other cells of the immune
system to locally produce hormonally active 1, 25-D from the inert
substrates cholecalciferol and 25-D. Through up-regulation of 1a-
OHase, DCs generate concentrations of 1, 25-D in culture that
approximate the pharmacological concentrations used for sup-
pression of MDDC maturation and inflammatory cytokine
secretion[65,66] Increased local DC production of 1, 25-D has
been proposed as a potential mechanism for controlling autoim-
mune responses in inflammatory sites.
These studies demonstrate that individuals with SLE have
MDDCs that display normal responsiveness to vitamin D resulting
in decreased activation. These studies additionally show that
vitamin D inhibits the overexpression of IFN regulated genes in
both normal and SLE derived MDDCs that are exposed to
activating plasma. It is unclear if vitamin D insufficiency confers
an increased likelihood of a genetically susceptible individual to
progress to a full autoimmune disease or if vitamin D insufficiency
is permissive for increased immunologic activation and disease
activity or both. Kamen et al, examining a different patient cohort
[47], reported lower serum 25-D levels among recently diagnosed
SLE patients suggesting that vitamin D deficiency may be a risk
factor for the development of SLE. Our current study and others
show an inverse relationship between vitamin D levels and disease
activity in established SLE. It is therefore possible to ask whether
increased serum vitamin D levels might lead to immunologic and
subsequent clinical improvement and so to demonstrate conclu-
sively whether vitamin D levels contribute to disease activity.
However, it is difficult to predict the amount of vitamin D
supplementation required to restore 25-D levels to a desired range.
New norms for vitamin D have been suggested through meta-
analyses relating serum levels of 25-D to fractures, falls and
neoplastic disease. These studies indicate that optimal levels of 25-
D should be above 30 ng/ml, however, it is unknown whether the
desired level for immune homeostasis is the same or different of
that needed for optimal bone health. Abrogation of the IFN
signature in SLE PBMC provides a measurable response to
vitamin D supplementation. The results of an ongoing phase I trial
studying the safety of 3 doses of vitamin D in SLE (Clinical-
Trials.gov Identifier: NCT00710021) and the results of a phase II
trial studying the effects of vitamin D supplementation on the IFN
signature are eagerly awaited.
In summary, vitamin D supplementation potentially provides a
non-toxic approach to improving immune regulation in SLE
patients. Our study contributes information on the prevalence of
vitamin D deficiency in SLE and association with disease activity.
It is the first study to demonstrate the inhibitory effects of 1, 25-D
on SLE MDDC activation and transfer of the IFN signature in vitro
and to show that MDDCs derived from SLE patients are
responsive to changes in 1, 25-D concentration. The study is
limited by the small samples sizes used in the experiments.
Adequately powered studies are needed to determine how best to
replenish body stores of vitamin D in patients with SLE and to
determine whether such supplementation is associated with a
reduction in IFNa activity and disease activity in patients with this
disease.
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